Opthea Ltd (ASX:OPT)
A$ 0.705 -0.015 (-2.08%) Market Cap: 867.92 Mil Enterprise Value: 820.54 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Opthea Ltd at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 15, 2023 / 10:00PM GMT
Release Date Price: A$0.781425 (-0.55%)
Rudy Li
SVB Securities - Analyst

Good afternoon, everyone. Welcome back to the next session of the SVB Securities Global Biopharma Conference. My name is Rudy Li, biopharma analyst of the SVB Securities equity research team.

So I'm very happy today to introduce management team of Opthea for a presentation to talk about the story of the company. Joining us today are Megan Baldwin, the CEO; and Timothy Morris, the CFO of the company. For the investors who join us today, feel free to submit any questions on the webcast.

Well, thanks for joining us, Megan. Now, the floor is yours.

Megan Baldwin
Opthea Limited - CEO & MD

Thanks, very much, Rudy, and thanks very much for the opportunity to take you through the Opthea story today. I'm going to tell you about our novel therapy, which is OPT-302. It's a trap molecule targeting novel members of the VEGF family, which is being used as a treatment in combination with standard of care therapies to give patients a better opportunity to improve visual acuity when they suffer from wet age-related

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot